ARID1A and gastric adenocarcinoma: These findings highlight cg05445839, a recurrently hypermethylated probe within the ARID1A promoter, as a potential therapeutic target for restoring physiological ARID1A expression in gastric adenocarcinoma through epigenetic modulation.